KR20240146013A - 치료진단적 폴레이트 접합체 - Google Patents

치료진단적 폴레이트 접합체 Download PDF

Info

Publication number
KR20240146013A
KR20240146013A KR1020247028652A KR20247028652A KR20240146013A KR 20240146013 A KR20240146013 A KR 20240146013A KR 1020247028652 A KR1020247028652 A KR 1020247028652A KR 20247028652 A KR20247028652 A KR 20247028652A KR 20240146013 A KR20240146013 A KR 20240146013A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
effective amount
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247028652A
Other languages
English (en)
Korean (ko)
Inventor
피올라 그뢴
렌츠-마리-루이스
루돌프 모저
로거 쉬블리
크리스티나 막달레나 뮐러
루이자 마리아 데베를레
안나 엘리자베트 벡커
자라 도리나 부쓸링거
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20240146013A publication Critical patent/KR20240146013A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247028652A 2022-02-01 2023-01-30 치료진단적 폴레이트 접합체 Pending KR20240146013A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22154652 2022-02-01
EP22154652.6 2022-02-01
PCT/EP2023/052117 WO2023148116A1 (en) 2022-02-01 2023-01-30 Theragnostic folate conjugates

Publications (1)

Publication Number Publication Date
KR20240146013A true KR20240146013A (ko) 2024-10-07

Family

ID=80118841

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247028652A Pending KR20240146013A (ko) 2022-02-01 2023-01-30 치료진단적 폴레이트 접합체

Country Status (9)

Country Link
US (1) US20250127938A1 (enExample)
EP (1) EP4472677A1 (enExample)
JP (1) JP2025504027A (enExample)
KR (1) KR20240146013A (enExample)
CN (1) CN118647412A (enExample)
AU (1) AU2023216406A1 (enExample)
CA (1) CA3243584A1 (enExample)
IL (1) IL314508A (enExample)
WO (1) WO2023148116A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025227100A2 (en) * 2024-04-26 2025-10-30 Purdue Research Foundation Targeted delivery of therapeutic agent to retinal pigment epithelium in treatment of ocular diseases

Also Published As

Publication number Publication date
CN118647412A (zh) 2024-09-13
WO2023148116A1 (en) 2023-08-10
CA3243584A1 (en) 2023-08-10
US20250127938A1 (en) 2025-04-24
AU2023216406A1 (en) 2024-09-19
EP4472677A1 (en) 2024-12-11
IL314508A (en) 2024-09-01
JP2025504027A (ja) 2025-02-06

Similar Documents

Publication Publication Date Title
CN109053616B (zh) 前列腺特异性膜抗原(psma)的标记的抑制剂及其用途
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
ES2844586T3 (es) Inhibidores del antígeno prostático específico de membrana (PSMA) etiquetados con 18F y su uso como agentes de obtención de imágenes para el cáncer de próstata
CN113573742A (zh) 新型肿瘤抗原结合剂及其用途
US20250108138A1 (en) Theragnostic folate conjugates
US20250127938A1 (en) Theragnostic folate conjugates
US10449261B2 (en) Compositions targeting radiation-induced molecules and methods of use thereof
US20250339568A1 (en) Precursor and radiotracer for neuroendocrine theranostics
HK40110380A (zh) 治疗诊断学叶酸酯缀合物
HK40109744A (zh) 治疗诊断学叶酸酯缀合物
JP2024530057A (ja) ネトリン－１検出、コンパニオン検査及び放射線に基づく療法
KR20230044463A (ko) 갈륨-표지된 가스트린 유사체 및 cckb 수용체 양성 종양 또는 암의 영상화 방법에서의 용도
EP4640240A1 (en) Peptide-based radiopharmaceuticals for non-invasive imaging of the functional liver reserve
Braz Mitochondria-Targeted 111In-Radiocomplexes for Auger Therapy of Prostate Cancer
WO2025191096A1 (en) Bicyclic peptide
AU2024344671A1 (en) Functionalized peptides for in-vivo addressing of pd-l1 expression
HK40054611A (en) Novel tumor antigen binding agents and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000